Rilvegostomig trials for Lung cancer
All Rilvegostomig trials · All Lung cancer trials
8
Recruiting trials
Phase breakdown
Phase 1 3Phase 2 4Phase 3 3
Recruiting trials studying Rilvegostomig for Lung cancer
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
- A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
- A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
- A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Common questions
How many trials study Rilvegostomig for Lung cancer?
8 recruiting trials.
Is this list complete?
No. For the full record, search ClinicalTrials.gov.